DongKoo Bio & Pharma Co Ltd
DongKoo Bio & Pharma Co Ltd maintains a debt-to-equity ratio of 0.85, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.92, suggesting that its current liabilities slightly exceed its current assets. Free cash flow for the period was 35,393,637,420 KRW, reflecting a positive cash flow after capital expenditures, which were -20,452,488,260 KRW. Profitability metrics show a return on equity (ROE) of 33.14% and a return on assets (ROA) of 14.95%, both of which are strong indicators of efficient capital utilization and asset management. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is generating returns that are competitive with or exceed industry norms. The company's revenue is derived from a diverse set of products and services, including medications for genitourinary and rectal organs, allergy treatments, antibiotics, topical dermatitis medications, and chemotherapeutic agents for fungal infections. Additionally, it operates as a CMO and sells medical devices and cosmetics. However, the input data does not provide specific revenue concentration by segment or geography, so it is not possible to determine if the company has significant exposure to any particular region or product line. The company's growth trajectory is not explicitly detailed in the input data, but the positive free cash flow and the absence of a significant increase in shares outstanding suggest a stable financial position. The input data does not provide specific revenue growth figures for the current or next fiscal year, so it is not possible to determine the exact direction or magnitude of the company's growth. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in the event of a liquidity crunch. However, the low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders. Recent events and filings are not detailed in the input data, so it is not possible to provide specific information on recent developments that may have impacted the company's financial position or strategic direction.
Business. DongKoo Bio & Pharma Co Ltd is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals, including medications for genitourinary and rectal organs, allergy treatments, antibiotics, topical dermatitis medications, and chemotherapeutic agents for fungal infections, as well as operating as a contract manufacturing organization (CMO) for pharmaceuticals and selling medical devices and cosmetics.
Classification. DongKoo Bio & Pharma Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a classification confidence of 0.92.
- DongKoo Bio & Pharma Co Ltd has a strong return on equity (33.14%) and return on assets (14.95%), indicating efficient capital and asset utilization.
- The company maintains a moderate debt-to-equity ratio of 0.85, suggesting a balanced capital structure.
- Free cash flow is positive at 35,393,637,420 KRW, indicating the company generates sufficient cash to cover capital expenditures and potentially fund growth initiatives.
- The company's liquidity position is assessed as medium, with a current ratio of 0.92, indicating that current liabilities slightly exceed current assets.
- The risk assessment indicates a medium liquidity risk and a low dilution risk, suggesting a stable financial position with limited threat to existing shareholders.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.